Table 4 OARSI responder criteria
From: Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis
Number (%) of Responders | 0.03 mg (N = 7) | 0.1 mg (N = 6) | 0.3 mg (N = 6) | 1 mg (N = 6) | All (N = 25) | Placebo (N = 8) |
|---|---|---|---|---|---|---|
Week 4 | 3 (42.9%) | 4 (66.7%) | 1 (16.7%) | 2 (33.3%) | 10 (40%) | 1 (12.5%) |
Week 8 | 3 (42.9%) | 4 (66.7%) | 2 (33.3%) | 2 (33.3%) | 11 (44%) | 0 (0%) |
Week 12 | 1 (14.3%) | 4 (66.7%) | 2 (33.3%) | 1 (16.7%) | 8 (32%) | 1 (12.5%) |
Week 24 | 1 (14.3%) | 5 (83.3%) | 2 (33.3%) | 1 (20%) | 9 (37.5%) | 1 (12.5%) |